Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Nanoparticle-Mediated Interleukin-12 Cancer Gene Therapy

    Access Status
    Fulltext not available
    Authors
    Hallaj-Nezhadi, S.
    Lotfipour, F.
    Dass, Crispin
    Date
    2010
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Hallaj-Nezhadi, S. and Lotfipour, F. and Dass, C. 2010. Nanoparticle-Mediated Interleukin-12 Cancer Gene Therapy. Journal of Pharmacy and Pharmaceutical Sciences. 13 (3): pp. 472-485.
    Source Title
    Journal of Pharmacy and Pharmaceutical Sciences
    Additional URLs
    http://ejournals.library.ualberta.ca/index.php/JPPS/article/view/8532
    ISSN
    1482-1826
    URI
    http://hdl.handle.net/20.500.11937/32598
    Collection
    • Curtin Research Publications
    Abstract

    Interleukin-12 (Il-12) is a heterodimeric cytokine which has been proven to possess antitumor effects in various animal models via stimulating the immune system. However, the main problem associated with Il-12 protein delivery is its instability as well as cytotoxicity subsequent to systemic administration in rodents and in clinical trials. However, gene delivery can be used to deliver genes of interest to the tumor site. Hence, a large number of studies have been undertaken to deliver genes of interest to the tumor site through viral or non-viral vectors. Viral DNA delivery systems suffer from safety concern due to the toxicity of the viruses and strong immune response, while non-viral gene delivery systems proffer lower transfection efficiency. In contrast, nanometer-sized complexes of therapeutic DNA may prove to be more efficient for administration of therapeutic genes to solid tumors compared to administration of naked plasmid DNA. Nanoparticle-based gene delivery systems might be more pertinent, due to enhanced tissue penetrability, and improved cellular uptake. Il-12 gene delivery has already been reported with different nanoparticles containing DNA. This article provides a review on the in vivo and in vitro studies using various nanoparticles, for delivery of the Il-12 gene to neoplastic cells. The future of these promising approaches lies in the development of better techniques for preparing Il-12 gene delivery systems with complete efficiency of viral vectors in addition to the highest safety for cancer patients.

    Related items

    Showing items related by title, author, creator and subject.

    • Diaminododecane-based cationic bolaamphiphile as a non-viral gene delivery carrier
      Khan, M.; Ang, C.; Wiradharma, N.; Yong, L.; Liu, S.; Liu, Lihong; Gao, S.; Yang, Y. (2012)
      The advancement in gene therapy relies upon the discovery of safe and efficient delivery agents and methods In this study, we report the design and synthesis of a cationic bolaamphiphile as a non-viral gene delivery agent ...
    • Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy
      Hallaj-Nezhadi, S.; Lotfipour, F.; Dass, Crispin (2010)
      While the systemic route of administration enables therapeutic genes to spread through the bloodstream and access target cells, it is a challenge to achieve this. Several studies demonstrate that systemic administration ...
    • Intraperitoneal delivery of nanoparticles for cancer gene therapy
      Hallaj-Nezhadi, Somayeh; Dass, Crispin; Lotfipour, Farzaneh (2013)
      Nanoparticle-based gene delivery systems may be more efficient for administration of therapeutic genes to solid tumors and cancer metastases, owing to the numerous advantages in terms of enhanced tissue penetrability, ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.